Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus Chemotherapy in Genetically Altered NSCLC
NCT03242915Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Oct 2017
- Primary completion
- Feb 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Percentage of Patients That Respond to Treatment at 5.5 years. Started Oct 2017; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03242915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03242915.